tiprankstipranks
Ascendis Pharma A/S (MX:ASND1N)
NASDAQ:ASND1N
ASND1N
Ascendis Pharma
RESEARCH TOOLSreports

Ascendis Pharma (ASND1N) Price & Analysis

― Followers

ASND1N Stock Chart & Stats

$3919.60
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range$3,131.06 - $4,326.49
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
$276.86B
Enterprise Value$15.13K
Total Cash (Recent Filing)$573.42M
Total Debt (Recent Filing)$897.60M
Price to Earnings (P/E)27.2
Beta-0.03
Next Earnings
Aug 06, 2026
EPS Estimate
29.85
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.19
Shares Outstanding62,376,846
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio1.13
Price to Book (P/B)-67.58
Price to Sales (P/S)15.90
P/FCF Ratio252.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)243.59
Revenue Forecast (FY)$23.39B

ASND1N FAQ

What was Ascendis Pharma A/S’s price range in the past 12 months?
Ascendis Pharma A/S lowest stock price was $3131.06 and its highest was $4326.49 in the past 12 months.
    What is Ascendis Pharma A/S’s market cap?
    Ascendis Pharma A/S’s market cap is $276.86B.
      When is Ascendis Pharma A/S’s upcoming earnings report date?
      Ascendis Pharma A/S’s upcoming earnings report date is Aug 06, 2026 which is in 11 days.
        How were Ascendis Pharma A/S’s earnings last quarter?
        Ascendis Pharma A/S released its earnings results on May 07, 2026. The company reported $194.397 earnings per share for the quarter, beating the consensus estimate of $3.23 by $191.167.
          Is Ascendis Pharma A/S overvalued?
          According to Wall Street analysts Ascendis Pharma A/S’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Ascendis Pharma A/S pay dividends?
            Ascendis Pharma A/S does not currently pay dividends.
            What is Ascendis Pharma A/S’s EPS estimate?
            Ascendis Pharma A/S’s EPS estimate is 29.85.
              How many shares outstanding does Ascendis Pharma A/S have?
              Ascendis Pharma A/S has 62,376,846 shares outstanding.
                What happened to Ascendis Pharma A/S’s price movement after its last earnings report?
                Ascendis Pharma A/S reported an EPS of $194.397 in its last earnings report, beating expectations of $3.23. Following the earnings report the stock price went same 0%.
                  Which hedge fund is a major shareholder of Ascendis Pharma A/S?
                  Currently, no hedge funds are holding shares in MX:ASND1N
                  What is the TipRanks Smart Score and how is it calculated?
                  Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                    Ascendis Pharma Stock Smart Score

                    9
                    Outperform
                    1
                    2
                    3
                    4
                    5
                    6
                    7
                    8
                    9
                    10

                    Blogger Sentiment

                    Neutral
                    MX:ASND1N Sentiment 50%
                    Sector Average 65%

                    News Sentiment

                    Very Bullish
                    Bullish news 100%
                    Bearish news 0%

                    Technicals

                    SMA
                    Positive
                    20 days / 200 days
                    Momentum
                    48.50%
                    12-Months-Change

                    Fundamentals

                    Return on Equity
                    ―
                    Trailing 12-Months
                    Asset Growth
                    101.31%
                    Trailing 12-Months
                    Top Smart Score Stocks >

                    Company Description

                    Ascendis Pharma A/S

                    Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.

                    Ascendis Pharma (ASND1N) Earnings & Revenues

                    Historic Earnings Reports

                    ASND1N Earnings Call

                    Q1 2026
                    0:00 / 0:00
                    Popular Stocks